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Macrolides have therapeutic benefits on chronic inflammatory airway diseases. Thus, macrolides are supposed to
have variable biological eects apart from antimicrobial activity. Neutrophil adherence and influx with oxidants
and cytokines production implicates involvement in airway inflammation. To investigate whether erythromycin
(EM) aects neutrophil activity in vitro, lipopolysaccharide (LPS)-treated neutrophils were continuously incubated
for 4 h in the absence or presence of increasing doses of EM from 1 g ml71 to 100 g ml71 in the last 2 h.
Leukocyte adhesion molecules Mac-1 and intracellular H2O2(DCFH) were determined by flowcytometric assay. IL-
8 and TNFa in supernatant was measured by ELISA method. The expression of Mac-1 and mean intracellular
DCF fluorescence intensity (DCFH) of neutrophils significantly increased after stimulation with LPS. Pretreatment
with EM significantly decreased LPS induced Mac-1 expression on neutrophils compared with LPS stimulation
only. EM alone (100 g ml71) also decreased Mac-1 expression on neutrophils. EM significantly reduced the LPS-
increased DCFH. EM alone (100 g ml71) also caused a decrease in DCFH. Increasing doses of EM also
significantly decreased the IL-8 released by LPS-stimulated neutrophils. In conclusion, EM exerts a direct eect on
the neutrophils by downregulating the expression of 2-integrin on neutrophils, thus leading to a decrease in the
intracellular H2O2, as well as the production of IL-8. Our conclusion provides an explanation for the clinical
ecacy of erythromycin in neutrophil-mediated airway inflammation.
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Erythromycin has long been used as an anti-infective agent
in bacterial exacerbations of chronic bronchitis and
community-acquired pneumonia. There is increasing evi-
dence showing erythromycin modulates neutrophil activ-
ities and then contributes to its clinical eectiveness in the
treatment of chronic inflammatory airway disease (1). To
date, however, there is no substantial evidence to show a
direct eect of erythromycin on neutrophil function.
Dense polymorphonuclear neutrophil (PMN) infiltration
in the airways is characteristic of inflammatory airway
diseases and significantly increases during airway infection
(2,3). The recruitment or sequestration of neutrophils is a
crucial host response against bacterial and fungal invasion
(4,5). Expression of adhesion molecules on PMNs, espe-Received 3 May 1999 and accepted in revised from 28 December
1999.
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2-integrins (CD11/CD18), mediates the chemotaxis,
transendothelial and transepithelial migration, as well as
phagocytosis and degranulation of PMNs (6). One major
bactericidal mechanism used by PMNs is the production of
reactive oxygen metabolites, together with hydrogen
peroxide (H2O2), hypochlorous acid (HOC1) and hydroxyl
radical (OH . ), during what is referred to as the oxidative
burst. However, excessive oxidant generation can also be
involved in cell and tissue damage associated with severe
inflammatory reaction (7). Moreover, activated PMNs in
the bronchial lumen are also capable of releasing pro-
inflammatory mediators, including IL-8 and TNFa (1)
which, when combined with toxic oxygen radical species,
including H2O2 and O
ÿ
2 may subsequently lead to epithelial
injury, mucociliary clearance impairment, and mucus
hyper-secretion (8,9). Thus, a fine tuned regulation of
neutrophil activation may be important in attaining a
balance between bactericidal response and tissue injury, in
terms of adhesion molecule expression, intracellular oxi-
dant production and pro-inflammatory cytokine release.
The present study was designed to examine the inflamma-
tion modulation eect of erythromycin on neutrophils in
the absence or presence of endotoxin stimulation.# 2000 HARCOURT PUBLISHERS LTD
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NEUTROPHIL PREPARATION
Neutrophils were prepared from heparinized peripheral
venous blood of healthy donors. Following 6% dextran
sedimentation of the red cells, the plasma layer containing
the leukocytes was centrifuged and washed twice with
phosphate-buered saline containing 5 mM glucose.
Washed cells were then layered over Ficoll and centrifuged
(750 g for 30 min) to separate neutrophils from mono-
nuclear cells. Contaminated red cells in the neutrophil pellet
were removed by hypotonic lysis, and the purified
neutrophils were washed once and re-suspended in Hank’s
balanced salt solution (HBSS). The final preparation
contained more than 95% neutrophils. Cell viability
exceeded 98% as determined by trypan blue exclusion.
PROTOCOL
Initially, neutrophils (16106 cells ml71) were cultured in
medium at 378C in 5% CO2 and stimulated with
lipopolysaccharide (LPS)(1 ng ml71) for 2 h, then the
LPS-pretreated neutrophils were continuously incubated
for another 2 h in the absence or presence of increasing
doses of erythromycin (Sigma Chemical Co., St. Louis.,
MO, U.S.A.) at 1–100 mg ml71. In time-course experiments,
the LPS-pretreated neutrophils were continuously incu-
bated for 30 min, 1, 2 and 4 h in the presence of selective
dose of erythromycin or its vehicle as a control. LPS-
stimulation was carried out before administration of
erythromycin to mimic erythromycin therapy in clinical
practice. Neutrophils incubated with LPS vehicle (saline)
for 4 h were used as a control. The direct eect of
erythromycin on unstimulated neutrophil activities was
examined by incubating neutrophils with erythromycin
(100 mg ml71) for 2 h without LPS stimulation. The cells
were then collected for measurements of surface adhesion
molecule (CD11b/CD18) expression and intracellular oxi-
dative metabolism. The supernatants were stored at7708C
for cytokine (IL-8 and TNFa) assay.
ADHESION MOLECULE EXPRESSION ON
NEUTROPHILS
Flow cytometric analysis
Analysis was performed with a FAScan flow cytometer
(Becton Dickinson, Mountain View, CA, U.S.A.) equipped
with a 5 W argon ion laser at 300 MW with 75 high voltage
setting and an excitation wavelength of 488 nm. The
emitted light was collected through 488 nm and 550 nm
dichloric filters. A 525-nm band-pass filter was used for
gating fluorescence emission, and a 570-nm long-pass filter
for scattering emission. All fluorescence was measured
using logarithm amplification. Granulocytes were identified
based on forward angle light scatter and log 908 scatter
parameters. Ten microlitres of propidium iodide was added
to each sample to distinguish leukocytes from non-viablecells. Cells after stimulation might have a dierent forward
angle and side (908) light scatter which requires a change in
the gates. In the case of the dual-colour analysis, overlap of
the green fluorescence and PE emission spectra was
eliminated by electronic substration. For histogram, 5000
leukocytes were analysed. The FACScan cytometer was
always operated at the same settings.
The expression of CD11b/CD18 (Mac-1) on neutrophils
was assessed by flow cytometry using phycoerythrin (PE)-
conjugated monoclonal rat antibody to the mouse and
human (DAKOPATTS a/s, Glostrup, Denmark). After
incubation in the presence or absence of stimulation, cells
were washed twice with PBS containing 5 mM glucose and
01% gelatin without Ca2 and Mg2(PBSg). The cells were
further incubated with anti-CD11b/CD18 (Mac-1) mono-
clonal antibodies for 20 min at 48C and subsequently
analysed by flow cytometry after two extensive washings
with cold PBSg containing 10% FCS. Analysis was
accomplished with a FACScan (Becton Dickinson by
gating 10 000 counts in the neutrophil region of the
forward and right angular scattergrams, and using the
non-binding IgG1 as a control. Results were expressed as a
mean of fluorescence intensities (MFI).
OXIDATIVE METABOLISM IN
NEUTROPHIL
Individual leukocyte respiratory burst response was as-
sessed by using 2171 dischlorofluorescin diacetate (DCFH-
DA) and flow cytometry (10). In brief, after incubation in
the presence or absence of stimulation, neutrophils were
pelleted and resuspended in PBSg at 106 cells ml71 and then
loaded with DCFH-DA (1 mM) for 15 min at 378C with
shaking. Cells were washed twice extensively with PBSg
containing 10% FCS, transferred to an ice bath and
subsequently analysed by flow cytometry.
CYTOKINES ASSAY IN THE SUPERNATANT
Immunoreactivities of IL-8 and TNFa in supernants were
measured using a sandwich-ELISA method using commer-
cial kits (Bender MedSystems Vienna, Austria).
STATISTICAL ANALYSIS
Data were presented as means + standard error of mean
(SEM). One-way analysis of variance for mixed design was
used to compare values of more than two dierent
experimental groups. If variance among groups was noted,
a Bonferroni test was used to determine significant
dierences between specific points within groups. A
Mann–Whitney U-test (two-tailed) or Wilcoxon signed
rank test was used for unpaired or paired data comparison
respectively. The relationship between the changes in Mac-1
(CD11b/CD18) expression and DCF oxidative capacity
was sought by Spearman’s rank correlation test. Signifi-
cance was at P5005.
FIG 2. The eect of erythromycin (EM) (1,10 and 100 g
ml71, n=8) on intracellular hydrogen peroxide
production [expressed by mean DCF fluorescence
intensity (MFI)] content in neutrophils after 4-h
stimulation with lipopolysaccharide (LPS, n=8) in
neutrophils in the presence or absence of LPS (1 mg ml71)
pretreatment. The significance is indicated. The values are
presented as mean+SEM. *P5005 compared with LPS
only. #P5005 compared with EM (—) LPS (–).
FIG 3. The relationship between the percentage change in
Mac-1 expression and the mean DCF fluorescence
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CD11B/CD18 EXPRESSION ON
NEUTROPHILS
The expression of adhesion molecule Mac-1 (CD11b/
CD18) on neutrophils significantly increased after stimula-
tion with LPS [2361+135 mean fluorescence intensity
(MFI); n=8], compared with control (2059+147, MFI;
P5001) (Fig. 1). Erythromycin (1, 10 and 100 mg ml71)
significantly decreased LPS induced Mac-1 expression on
neutrophils (2005+145, 1847+95 and 1896+120,
MFI; P5001; n=8, respectively) compared with LPS
stimulation only (Fig. 1). Without LPS stimulation,
erythromycin alone (100 mg ml71) also decreased Mac-1
expression on neutrophils (1693+111, MFI; P5005;
n=8) compared with the control (Fig. 1).
THE INTRACELLULAR OXIDATIVE
CAPACITY
The mean intracellular DCF fluorescence intensity (DCFH)
significantly increased with LPS stimulation to 455+103
MFI (n=8; P5005) compared with that of control
(211+32 MFI, n=8) (Fig. 2). Erythromycin (1, 10 and
100 mg ml71) significantly reduced the LPS-increased mean
DCF fluorescence intensity to 252+76, 217+41 and
222+39 MFI, respectively (n  8; P5005) (Fig. 2).
Without LPS stimulation, erythromycin also decreased
the mean DCF fluorescence intensity (150+39 MFI;
P5005; n  8) compared with that of control (Fig. 2).
The magnitudes that erythromycin (100 mg ml71) re-
duced the Mac-1 expression on LPS-stimulated neutrophils
was significantly correlated with the changes in the mean
DCF fluorescence intensity (rs  0  81; n  8; P < 0  05)
(Fig. 3).FIG 1. The eect of erythromycin (EM) (1,10 and
100 g ml71 n=8) on adhesion molecule Mac-1 (CD11b/
CD18) expression on neutrophils after 4 h stimulation
with lipopolysaccharide (LPS, n=8) in the presence or
absence of LPS (1 mg ml71) pretreatment. The
significance is indicated. The values are presented as
mean+SEM. *P5001 compared with LPS only.
##P5001 compared with EM (—) LPS (–). #P5005
compared with EM (—) LPS (–).
intensity inhibited by erythromycin (100 g ml71). n=8;
rs=081; P5005.THE TIME-COURSE FOR
ERYTHROMYCIN’S INHIBITION OF
ADHESION MOLECULE EXPRESSION AND
OXIDANT PRODUCTION
Based on above results, erythromycin 1 mg ml71 was chosen
for further time-course experiments. The expression of
Mac-1 on LPS-stimulated neutrophils significantly in-
creased after 30 min (2156+88 MFI; P5005), 1 h
(2267+218 MFI; P<001), 2 h (2373+222 MFI;
P<001) and 4 h of incubation (2332+145 MFI;
P<00), compared with baseline (2059+147, MFI) [Fig.
4(a)]. Incubation with erythromycin was associated with a
time-dependent reduction of Mac-1 expression, reaching
the nadir at 4 h (1614+154 MFI) [Fig. 4(a)]. The
generation of DCFH in LPS-stimulated neutrophils
reached a peak at 2 h (460+88 MFI; P5001) after
incubation, compared with baseline (211+32 MFI;
FIG 4. The time-course for the inhibitory eect of
erythromycin (1 g ml71, n=5) on (a) adhesion molecule
expression (*P5005 compared with LPS+EM; and
**P50001 compared with LPS+EM;) (b) oxidant
production in LPS-activated neutrophils (*) compared
with LPS-activated neutrophils without erythromycin (*)
(*P5001 compared with (LPSEM). The significance is
indicated. The values are presented as mean+SEM.
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decrease in LPS-stimulated DCFH generation after incuba-
tion with erythromycin [Fig. 4(b)].
CYTOKINE RELEASE
Erythromycin (1, 10 and 100 mg ml71) significantly de-
creased the LPS-induced IL-8 release by neutrophils
(1750+643, 1789+894 and 1454+575 pg ml71;TABLE 1. The in vitro eect of erythromycin (EM) on the prod
(TNF-) by the neutrophils
EM (g ml71) – 100
LPS (ng ml71) – –
IL-8 (pg ml71) 2568+828 1735+650 2823
TNF- (pg ml71) 143+37 87+20 168
EM: erythromycin, LPS: lipopolysaccharide.
The values are presented as mean+SEM, n=8.
*P5005 compared with LPS only.
{P5005 compared with LPS (–) EM (–).P5005; n  8, respectively) compared with LPS-stimula-
tion only (2823+720 pg ml71) (Table 1). Without LPS
stimulation, erythromycin (100 mg ml71) also decreased the
spontaneous release of IL-8 by neutrophils (1735+650
pgml71), compared with that released from incubation
alone (2568+838 pg ml71). In contrast, erythromycin did
not significantly influence TNFa production (Table 1).
Discussion
The present study demonstrates that erythromycin signifi-
cantly decreases the expression of surface adhesion
molecules, 2-integrins (CD11b/CD18), the production of
intracellular hydrogen peroxide (H2O2), as well as IL-8
release by neutrophils in the presence or absence of LPS
stimulation.
The expression of adhesion molecules, especially CD11b/
CD18 is closely related to neutrophil adherence and
chemostaxis. Several reports have suggested that erythro-
mycin may inhibit neutrophil chemotaxis (11) and endo-
toxin-induced neutrophil sequestration (12). However,
Anderson et al. (13) showed that erythromycin might
potentiate neutrophil locomotion. Recently, Carvalho et al.
(14) proposed that erythromycin had a potential role as a
sclerosant by producing pleural inflammation. Therefore,
the exact influence of erythromycin in human inflammatory
cell activities is still obscure. It is well established that 2-
integrins are implicated in neutrophil recruitment and
transmigration, and also play an important role in
regulation of phagocytosis (15). Recently, macrolides have
been shown to suppress the expression of Mac-1 (CD11b/
CD18) on neutrophil and alleviate local alveolar injury
(16). Our results also demonstrated that erythromycin
inhibited Mac-1 expression on LPS-stimulated or unstimu-
lated neutrophils, suggesting the chemotactic eect of
erythromycin on neutrophils may be through a direct
suppression of surface adhesion molecules expression.
The increased expression of Mac-1 molecule on the
surface of neutrophils also result in more ecient
intracellular transduction of stimuli and in adhesion
dependent oxidants generation (17) that is implicated in
further airway inflammation and epithelial destruction (18).
Shappell et al. (19) suggested that the H2O2 production is
adherence-dependent and mediated by expression of Mac-1uction of interleukin-8 (IL-8) and tumour necrosis factor-
– 1 10 100
1 1 1 1
+720 1750+648* 1789+894* 1454+575*
+79 65+08 67+13 71+05
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a correlation between oxidative metabolism and Mac-1
expression in alveolar macrophages in patients with active
pulmonary tuberculosis. Our data shows that erythromycin
not only reduces the leukocyte 2-integrins (CD11b/CD18)
expression on neutrophils, but also decreases the associated
oxidant production. Moreover, the magnitude of decrease
in H2O2 is significantly corelated to the reduction of Mac-1,
reflecting the anti-oxidant eect of erythromycin may be
due to its anti-adhesive action on neutrophils. Macrolides
could reach a higher intracellular concentration, and then
may in turn directly alter the neutrophil functions which
appear crucial for the inflammatory process (21). It is not
known whether erythromycin may directly influence
intracellular oxidative metabolism.
The anti-oxidant action has been postulated responsible
for the clinical eectiveness of erythromycin in the manage-
ment of diuse panbronchiolitis, whose pathogenesis may
be due to neutrophils and their derived toxic oxygen
radicals (11). Other macrolides, such as roxithromycin, are
also suggested to possess a similar anti-inflammatory action
by inhibiting neutrophil oxygen radical generation (22).
Our findings therefore provide further confirmation that
erythromycin will reduce the intracellular oxidant (H2O2)
content of neutrophils, suggesting that the clinically
therapeutic eectiveness of erythromycin for these inflam-
matory airway diseases may be related to a reduction in the
intra-pulmonary burden of oxidants produced by activated
neutrophils.
IL-8 is a chemotactic cytokine with main actions of
neutrophil recruitment and activation (12,23). Richman-
Eisenstat et al. (24) reported that IL-8 is an important
chemoattractant and is present at a high concentration in
the sputum of patients with chronic inflammatory airway
diesease, such as bronchiectasis and cystic fibrosis. Keatings
et al. (25) concluded that the increase of IL-8 in induced
sputum from patients with chronic obstructive pulmonary
disease might be released by inflammatory cells that are
sequestrated in the airways, especially neutrophils. Re-
cently, erythromycin has been demonstrated to decrease the
IL-8 level in the airways of patients with chronic airway
diseases (26–28). Our results revealed a direct inhibitory
eect of erthromycin on IL-8 production by LPS-stimu-
lated neutrophils and thus suggest that erythromycin also
exerts a potential role in chronic inflammatory airway
diseases by inhibiting the pro-inflammatory cytokines,
especially IL-8, release from neutrophils.
Kuo and colleagues (29) suggest that TNFa stimulation
may release IL-8 in airways mediated via an increase in
intracellular oxidant stress. Therefore, whether erythromy-
cin downregulates the release of IL-8 via a modulatory
eect on the oxidative metabolism deserves further
investigation. In the airways, IL-8 may be produced by
other inflammatory cells, such as monocytes (25), as well as
airway epithelial cells (29). It is interesting to investigating
whether the clinical eectiveness of erythromycin may be
also attributed to an inhibition of IL-8 production from
these cellular sources.
Since IL-8 is well known to alter the functional state of
the 2-integrins and thus may contribute to recruitment andaherence of neutrophils (30), the release of IL-8 from
neutrophils may self-perpetuate the activation of leukocytes
to regulate their adherence and associated oxidants
production. Based on our results, it is possible that
erythromycin downregulates the expression of CD11b/
CD18 partly through an inhibition of IL-8 production.
TNFa has also been implicated in the pathogenesis of
many inflammatory airway diseases. In the present study,
we did not find a significant eect of erythromycin on the
TNFa produced by neutrophils in vitro, which was
consistent with previous clinical studies (28) on the eect
of macrolides on TNFa level in bronchoalveolar lavage
fluid of patients with diuse panbronchiolitis. However,
erythromycin was reported to inhibit TNFa production
induced by heat-killed Streptococcus pneumoniae (HKSP) in
whole blood (31). Previous reports have suggested that
monocytes or macrophages are the major cellular source of
TNFa. Thus, the discrepancy between our results and those
from studies with whole blood stimulated by HKSP (31)
may be the present of monocytes or macrophages in the
whole blood.
The eective concentration of erythromycin in this study
was as low as 1 mm ml71, which is relevant to the plasma
plateau level of 11–12 mm ml71 at 26 h after a dosage of
oral erythromycin 30–60 mg kg71 day71 in healthy indi-
viduals (32). However, the responses to higher concentra-
tions of erythromycin in our study were not in a
concentration-dependent fashion. Several studies have
demonstrated that low-dose erythromycin treatment is
eective in the management of chronic airway diseases.
Khair et al. (33) reported that incubation of cultured
epithelial cells with ertyhromycin at concentration of
01 mm ml71 significantly blocked H. influenzae endotoxin
(HIE)-induced IL-6 and IL-8 release. Increasing concentra-
tion of erythromycin to 1 and 10 mmml71 did not
concentration-dependently enhance the response. It is
possible that erythromycin may be eective at much lower
concentrations, and thus the concentrations we used have
reached a plateau.
Our results showed that erythromycin not only down-
regulated the Mac-1 expression, oxidant metabolism, and
IL-8 production of stimulated neutrophils, but also of
resting neutrophils, suggesting that the eect of erythro-
mycin could have resulted from an inhibition of surface
protein binding receptors or intracellular signal transduc-
tional pathway. Recently studies had also raised the
possibility that CD11/CD18 may be capable per se of
transducing intracellular signals (34). The report from
Altieri et al. (35) suggested that occupancy of CD18
transduces a stimulatory Ca2 signal that is critically
regulated by the state of cell activation/dierentiation and
by the association with the unique a-subunit CD11b.
Whether erythromycin regulates the expression of CD11b/
CD18 by an eect on the Ca2 signalling remains to be
studied (36).
Taken together, our studies suggest that erythromycin
exerts a direct eect on the neutrophils. Erythromycin
downregulates the expression of 2-integrin (CD11b/Cd18)
on neutrophils, thus leading to a decrease in the intracel-
lular H2O2 concentration of neutrophils, as well as the
ERYTHROMYCIN MODULATES NEUTROPHIL ACTIVATION 659production of pro-inflammatory cytokine, IL-8. Our
conclusion provides an explanation for the clinical ecacy
of erythromycin in the treatment of neutrophil mediated
airway inflammation.
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